Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of dasatinib (BMS-354825) for advanced 'triple-negative' breast cancer.

Trial Profile

Phase II study of dasatinib (BMS-354825) for advanced 'triple-negative' breast cancer.

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Oct 2008 Checked against the ClinicalTrials.gov record.
    • 28 Sep 2008 Actual number of patients enrolled was 44 according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top